Master Alliance Provisions Guide (MAPGuide)

MPP – Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement

  • Protecting & sharing information | Confidentiality

7. Confidentiality and Publications

7.1 Confidential Information. All technology, know-how, business information, (including the annual and quarterly reports required by Section 3.7 hereof) or any other confidential information disclosed by one party to the other party shall be governed by the terms of the mutual Nondisclosure Agreement with an effective date of December 10, 2019 as executed by the Parties (“NDA”).

7.2 Publicity. Each Party shall seek each other’s previous written approval of any initial press release or public announcement concerning the grant, scope or terms of this licence prior to such press release or other publication being made. Following an initial announcement, neither Party shall be required to seek the other Party’s consent to make public statements, by press release or otherwise, regarding the existence of this Agreement, the identity of the Parties, the terms, conditions and subject matter of this Agreement, or otherwise in reference to this Agreement, provided such statements are accurate and not misleading and have been previously approved for release by the parties. It is understood and accepted by Licensee that MPP will publish the full contents of this Agreement on its website as of the Effective Date, and that Licensee and its Affiliates may include the terms and details of this Agreement, including the name of MPP, in its periodic public reports and may make that information available on their respective websites and as part of public records, tax returns and other similar public disclosures.

7.3 Other Use of Licensee Name. Except as set forth herein, including Section 7.2, MPP will not use the names, marks, logos, or trade dress of Licensee or its Affiliates (including the Bill & Melinda Gates Foundation and its trustees) in any public or promotional materials (including printed materials, email signatures, business cards, client lists, letterhead and the like) without the prior written consent of Licensee.